Glaxosmithkline Stock News

Wedbush Securities Inc. cut its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 44.0% during the 3rd quarter, Holdings Channel reports. The firm owned 15,148 shares of the pharmaceutical companys stock after selling 11,922 shares during the period. Wedbush Securities Inc.s holdings in GlaxoSmithKline were worth $579,000 as of its most recent filing with the []

The global cluster headache market is estimated to be valued at US$ 355.2 Million in 2021 and is expected to increase to US$ 550.1 Million by 2028, witnessing a CAGR of 6.4% over the forecast period (2021-2028). Cluster headache is one

Lupus Therapeutic Market report considers the latest upgrades while assessing the development of leading market players. This global market report is comprehensive and opens a door of worldwide market for the products. The report gives helpful insights which assist while

IFG Advisory LLC lifted its position in GlaxoSmithKline plc (NYSE:GSK) by 27.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,666 shares of the pharmaceutical companys stock after purchasing an additional 6,681 shares during the quarter. IFG Advisory LLCs holdings in []

Deutsche Bank Aktiengesellschaft restated their hold rating on shares of GlaxoSmithKline (LON:GSK) in a research note released on Wednesday morning, PriceTargets.com reports. They currently have a GBX 1,350 ($17.64) target price on the stock. GSK has been the subject of several other research reports. Barclays lifted their price target on GlaxoSmithKline from GBX 1,400 ($18.29) []

Rothschild Investment Corp IL lessened its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 4.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,700 shares of the pharmaceutical companys stock after selling 1,283 shares during the quarter. Rothschild Investment []

Old Port Advisors lifted its stake in GlaxoSmithKline plc (NYSE:GSK) by 0.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,163 shares of the pharmaceutical companys stock after buying an additional 563 shares during the period. GlaxoSmithKline makes up 1.0% of []

The global Cancer Vaccines market was valued at 4622.44 Million USD in 2020 and will grow with a CAGR of 13.89% from 2021 to 2027. Major factors driving market growth include an increase in the number of cancer patients, an

The recent research report on the Global HTLV-1 Associated Myelopathy (HAM) Drugs Market is aimed to offer data regarding the major work that is happening in the industry over the last few years. It gives a complete analysis of the

Antiallergics drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.90% in the above mentioned forecast period. The Antiallergics

Shigellosis Gastroenteritis Treatment Market report considers the latest upgrades while assessing the development of leading market players. This global market report is comprehensive and opens a door of worldwide market for the products. The report gives helpful insights which assist

Data Bridge Market research released a new market study on Human Papillomavirus Vaccine with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In Human Papillomavirus Vaccine research report also

LOWER GWYNEDD, Penn. , Nov. 19, 2021 /PRNewswire/ -- Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addition, the funding will also be used to accelerate the CMC and IND development of multiple other oncology pipelines and the development of the company''s multicyclic intracellular peptide (MIP) programs. Tavotek Biotherapeutics, established in early 2019, is committed to using innovation to improve the well-being of patients with unmet medical needs. The company has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China.

Next year will be a landmark one for GlaxoSmithKline, according to CEO Emma Walmsley though many of the biggest changes she forecasted may not become evident until next year.

The FTSE 100 extended losses for a third day and was set to end the week lower after gaining for three straight weeks, as a robust jobs report and data showing inflation at a 10-year high earlier this week heightened rate hike expectations. "Mounting inflation has helped drag the index back as it raises the likelihood of a pre-Christmas rate rise, thereby boosting the pound," said AJ Bell investment director Russ Mould.